Blocking IL-1: interleukin 1 receptor antagonist in vivo and in vitro.
about
Refined crystal structure of the interleukin-1 receptor antagonist. Presence of a disulfide link and a cis-prolineA cardiovascular drug rescues mice from lethal sepsis by selectively attenuating a late-acting proinflammatory mediator, high mobility group box 1Cytokine-mediated inflammatory hyperalgesia limited by interleukin-1 receptor antagonistIntestinal secretory factor released by macrophages stimulated with Clostridium difficile toxin A: role of interleukin 1beta.Suppression of experimental arthritis by gene transfer of interleukin 1 receptor antagonist cDNA.Optimization of scAAVIL-1ra In Vitro and In Vivo to Deliver High Levels of Therapeutic Protein for Treatment of Osteoarthritis.Human interleukin-1 receptor antagonist is expressed in liver.A major ingredient of green tea rescues mice from lethal sepsis partly by inhibiting HMGB1Role of CD40-CVD40L in mouse severe malaria.Interleukin-1 (IL-1) receptor antagonist prevents Staphylococcus epidermidis-induced hypotension and reduces circulating levels of tumor necrosis factor and IL-1 beta in rabbitsIntramuscular gold decreases cytokine expression and macrophage numbers in the rheumatoid synovial membrane.Cytokines and reproductionAn effector role for platelets in systemic and local lipopolysaccharide-induced toxicity in mice, mediated by a CD11a- and CD54-dependent interaction with endothelium.Lack of association between an interleukin-1 receptor antagonist gene polymorphism and ulcerative colitis.Novel HMGB1-inhibiting therapeutic agents for experimental sepsis.High mobility group box 1 protein as a potential drug target for infection- and injury-elicited inflammation.The Therapeutic Potential of Anti-Inflammatory Exerkines in the Treatment of AtherosclerosisInflammatory mediators in gastroesophageal reflux disease: impact on esophageal motility, fibrosis, and carcinogenesis.Suramin interferes with interleukin-6 receptor binding in vitro and inhibits colon-26-mediated experimental cancer cachexia in vivo.PKM2 regulates the Warburg effect and promotes HMGB1 release in sepsis.Treating inflammatory bowel disease by adsorptive leucocytapheresis: a desire to treat without drugs.Interleukin-1 receptor antagonist decreases bone loss and bone resorption in ovariectomized rats.The inhibitory effect of PIK-75 on inflammatory mediator response induced by hydrogen peroxide in feline esophageal epithelial cellsNeutralization of endogenous IL-1 receptor antagonist exacerbates and prolongs inflammation in rabbit immune colitis.Deficiency of C-C chemokine receptor 5 suppresses tumor development via inactivation of NF-κB and upregulation of IL-1Ra in melanoma modelNew Frontiers in Cytokine Involvement during Experimental Sepsis.Intraarticular expression of biologically active interleukin 1-receptor-antagonist protein by ex vivo gene transferQuantification of biological network perturbations for mechanistic insight and diagnostics using two-layer causal models.Differences in signaling pathways by IL-1beta and IL-18.More tea for septic patients?--Green tea may reduce endotoxin-induced release of high mobility group box 1 and other pro-inflammatory cytokines.HMGB1 in health and disease.Interleukin 1 induces expression of the human immunodeficiency virus alone and in synergy with interleukin 6 in chronically infected U1 cells: inhibition of inductive effects by the interleukin 1 receptor antagonist.The heme oxygenase-1 inducer THI-56 negatively regulates iNOS expression and HMGB1 release in LPS-activated RAW 264.7 cells and CLP-induced septic mice.Biologic therapies for juvenile arthritisInterleukin-1β and interleukin-1 receptor antagonist appear in grey matter additionally to white matter lesions during experimental multiple sclerosisBrain interleukin-1β and the intrinsic receptor antagonist control peripheral Toll-like receptor 3-mediated suppression of spontaneous activity in rats.The multifaceted effects of polysaccharides isolated from Dendrobium huoshanense on immune functions with the induction of interleukin-1 receptor antagonist (IL-1ra) in monocytesInterleukin 1 beta and corticotropin-releasing factor inhibit pain by releasing opioids from immune cells in inflamed tissue.Five genetic markers in the interleukin 1 family in relation to inflammatory bowel disease.Mechanisms of endotoxin tolerance in patients with alcoholic liver cirrhosis: role of interleukin 10, interleukin 1 receptor antagonist, and soluble tumour necrosis factor receptors as well as effector cell desensitisation.
P2860
Q27730381-C2A7F0AF-48A9-4A5C-9FCB-D289E2F5984DQ28220038-88EDE1E2-7321-4438-874E-CD84CD7CE822Q28583823-37F5AAD4-E0B0-4270-B774-F51E69CFABB2Q30453723-5D1A2793-E7C3-4651-914F-95F4F44B0DAEQ30453928-3B589868-9B53-40CF-B5E2-C72FD557582BQ30537079-A429942F-35D3-468B-B797-EC9F68360C55Q33190391-D15D8767-E60C-493A-BF86-E8AA733D8282Q33305218-30F306F3-7AFB-43DE-80A8-CEE8C2FCBC63Q33338408-420BB789-AF1F-484F-B9A0-D764D79B4829Q33493710-2F983836-D037-4DAF-A06D-049851AC804DQ33566324-FF1F7CC6-61A6-4BC8-A4F8-82ECF611FF85Q33607792-B56ADA17-3049-4E42-A2E0-AB65C26F806EQ33610571-B5BF89B6-7271-44F6-AB7F-1F0851BD4D83Q33618092-8E70334C-4670-4D14-8973-3AA3573CD436Q33814903-4D8CE2F4-5A7F-4286-A398-DDC03CA24B58Q33836853-068464FE-7529-4613-B002-3BD286FDAF85Q33838927-D80F3D6C-C026-46B2-B82C-9CC18E1D8026Q33840598-02B6D28D-8E99-4947-8518-2398065A8E9EQ33906984-353209B3-CB58-4920-B6D3-FFAE0D6EB8EBQ33926167-6B2F3355-3082-46E1-A665-8B1F2857D5F7Q34008773-013733F7-F25E-4EB2-9AA8-0890BBD1719AQ34143196-D366B41A-BA8C-429C-B7C5-CF8F68747A0CQ34222253-5026C619-DCD7-46D2-864C-D4690B27F35BQ34236293-3009D589-405B-433D-8998-9EC07F79B473Q34261494-3D310A68-CBA2-4E91-B728-41CB0C49B3DBQ34282716-EC2AF96A-434B-4885-A9EC-DADD236065C2Q34345395-387CC966-584E-4AAB-8247-BE6F5E889725Q34486361-81DEB036-CF6D-4693-B596-256A571105A2Q34515880-8F6BB6C2-3B6D-4E89-AD90-E598FBCE613BQ34565303-51490E44-E387-4393-95CF-A9EAF40B49D0Q34622835-02BF2D1C-BC90-490A-9462-3751D8E4D5ADQ34900183-9A7AB8E3-AD9B-4A89-9E12-92BD1A522E3DQ35009352-CD340ADF-4FB9-4BF6-948E-941290E0B7DEQ35070925-13674712-86A9-4F05-B7BD-500B980AA1CCQ35078252-FD565AEF-0FB5-4328-981C-7E9AFE2AFD87Q35118685-7F5B8016-63B7-438A-9B7B-0A264826821FQ35140248-030B480D-60B7-4031-8A51-86640FC08236Q35221862-69ACCE3B-3E72-4C57-9C52-E230D2BB4E3CQ35351628-85C336C4-5315-4200-8768-38F1541904F0Q35360983-EB99F91E-E06B-4B68-83B5-22DB39423860
P2860
Blocking IL-1: interleukin 1 receptor antagonist in vivo and in vitro.
description
1991 nî lūn-bûn
@nan
1991年の論文
@ja
1991年学术文章
@wuu
1991年学术文章
@zh-cn
1991年学术文章
@zh-hans
1991年学术文章
@zh-my
1991年学术文章
@zh-sg
1991年學術文章
@yue
1991年學術文章
@zh
1991年學術文章
@zh-hant
name
Blocking IL-1: interleukin 1 receptor antagonist in vivo and in vitro.
@en
Blocking IL-1: interleukin 1 receptor antagonist in vivo and in vitro.
@nl
type
label
Blocking IL-1: interleukin 1 receptor antagonist in vivo and in vitro.
@en
Blocking IL-1: interleukin 1 receptor antagonist in vivo and in vitro.
@nl
prefLabel
Blocking IL-1: interleukin 1 receptor antagonist in vivo and in vitro.
@en
Blocking IL-1: interleukin 1 receptor antagonist in vivo and in vitro.
@nl
P1433
P1476
Blocking IL-1: interleukin 1 receptor antagonist in vivo and in vitro.
@en
P2093
Thompson RC
P304
P356
10.1016/0167-5699(91)90142-G
P577
1991-11-01T00:00:00Z